[HTML][HTML] Topical and conventional systemic treatments in atopic dermatitis: have they gone out of fashion?
G Calabrese, G Licata, A Gambardella… - Dermatology Practical …, 2022 - ncbi.nlm.nih.gov
Atopic dermatitis is a Th2 disease, due to relapse of IL-4 and IL-13 by Th2 cells. Despite the
approval by FDA of dupilumab, the first monoclonal antibody for the severe forms, traditional …
approval by FDA of dupilumab, the first monoclonal antibody for the severe forms, traditional …
[PDF][PDF] Dermatol Pract Concept
G Calabrese, G Licata, A Gambardella, A De Rosa… - 2022 - academia.edu
Atopic dermatitis (AD) is a chronic, inflammatory skin disease, characterized by a
multifactorial pathogenesis. AD is considered a prototypical Th2 disease, due to relapse of …
multifactorial pathogenesis. AD is considered a prototypical Th2 disease, due to relapse of …
Topical and Conventional Systemic Treatments in Atopic Dermatitis: Have They Gone Out of Fashion?
G Calabrese, G Licata, A Gambardella… - Dermatology Practical & …, 2022 - dpcj.org
Atopic dermatitis is a Th2 disease, due to relapse of IL-4 and IL-13 by Th2 cells. Despite the
approval by FDA of dupilumab, the first monoclonal antibody for the severe forms, traditional …
approval by FDA of dupilumab, the first monoclonal antibody for the severe forms, traditional …
[PDF][PDF] Dermatol Pract Concept
G Calabrese, G Licata, A Gambardella, A De Rosa… - 2022 - pdfs.semanticscholar.org
Atopic dermatitis (AD) is a chronic, inflammatory skin disease, characterized by a
multifactorial pathogenesis. AD is considered a prototypical Th2 disease, due to relapse of …
multifactorial pathogenesis. AD is considered a prototypical Th2 disease, due to relapse of …
Topical and Conventional Systemic Treatments in Atopic Dermatitis: Have They Gone Out of Fashion?
G Calabrese, G Licata, A Gambardella… - Dermatology Practical …, 2022 - europepmc.org
Atopic dermatitis is a Th2 disease, due to relapse of IL-4 and IL-13 by Th2 cells. Despite the
approval by FDA of dupilumab, the first monoclonal antibody for the severe forms, traditional …
approval by FDA of dupilumab, the first monoclonal antibody for the severe forms, traditional …
Topical and Conventional Systemic Treatments in Atopic Dermatitis: Have They Gone Out of Fashion?
G Calabrese, G Licata, A Gambardella… - Dermatology Practical & …, 2022 - dpcj.org
Atopic dermatitis is a Th2 disease, due to relapse of IL-4 and IL-13 by Th2 cells. Despite the
approval by FDA of dupilumab, the first monoclonal antibody for the severe forms, traditional …
approval by FDA of dupilumab, the first monoclonal antibody for the severe forms, traditional …
Topical and Conventional Systemic Treatments in Atopic Dermatitis: Have They Gone Out of Fashion?
G Calabrese, G Licata, A Gambardella… - DERMATOLOGY …, 2022 - iris.unicampania.it
Atopic dermatitis is a Th2 disease, due to relapse of IL-4 and IL-13 by Th2 cells. Despite the
approval ABSTRACT by FDA of dupilumab, the first monoclonal antibody for the severe …
approval ABSTRACT by FDA of dupilumab, the first monoclonal antibody for the severe …
Topical and Conventional Systemic Treatments in Atopic Dermatitis: Have They Gone Out of Fashion?
G Calabrese, G Licata… - Dermatology …, 2022 - pubmed.ncbi.nlm.nih.gov
Atopic dermatitis is a Th2 disease, due to relapse of IL-4 and IL-13 by Th2 cells. Despite the
approval by FDA of dupilumab, the first monoclonal antibody for the severe forms, traditional …
approval by FDA of dupilumab, the first monoclonal antibody for the severe forms, traditional …
Topical and Conventional Systemic Treatments in Atopic Dermatitis: Have They Gone Out of Fashion?
G Calabrese, G Licata, A Gambardella… - Dermatology Practical …, 2022 - europepmc.org
Atopic dermatitis is a Th2 disease, due to relapse of IL-4 and IL-13 by Th2 cells. Despite the
approval by FDA of dupilumab, the first monoclonal antibody for the severe forms, traditional …
approval by FDA of dupilumab, the first monoclonal antibody for the severe forms, traditional …